- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07941726
Effect of GABAergic Treatments on Cortical Plasticity and Motor Learning Capacity in the Subacute Phase After Stroke (GABAPLAST)
Effect of GABAergic Treatments on Cortical Plasticity and Motor Learning Capacity in the Subacute Phase After Stroke: a Single-case Experimental Study
The GABAPLAST study explores how commonly prescribed GABAergic drugs prescribed during post-stroke rehabilitation affect cortical plasticity and motor learning capacity. Using a multiple-baseline single-case design, the study evaluates the effects of Baclofen, Oxazepam, and Gabapentin in subacute stroke patients according to their clinical indication. Cortical plasticity capacity is measured with transcranial magnetic stimulation and Paired Associative Stimulation (TMS/PAS). The study aims to determine whether these drugs interfere with or preserve brain plasticity during recovery.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Scientific rationale Functional recovery after stroke relies on neuroplasticity, the brain's ability to reorganize neural connections. During the subacute phase, high synaptic plasticity allows efficient motor relearning, but GABAergic inhibition may reduce these mechanisms. Several animal and human studies suggest that increased GABAergic activity limits long-term potentiation of plasticity (LTP-like) and motor learning. Baclofen (GABA-B agonist), Oxazepam (GABA-A agonist), and Gabapentin (GABA modulator) are routinely prescribed to treat spasticity, anxiety, or neuropathic pain after stroke, yet their neurophysiological effects remain unclear. GABAPLAST aims to provide the first controlled experimental evidence of their direct influence on cortical plasticity and implicit motor learning in subacute stroke patients.
Treatment/strategy/procedure and follow up
The study comprises 26 repeated assessment sessions performed five times per week, from Monday to Friday, over approximately six weeks. Each participant will receive one of the following medications according to their clinical indication: oxazepam for anxiety; baclofen for spasticity; gabapentin for neuropathic pain. Each participant will undergo two consecutive phases:
- Phase A: baseline phase without exposure to the study medication;
- Phase B: phase with exposure to the study medication, including dose titration and treatment at the clinically appropriate dose.
The duration of Phase A will be randomized to 6, 9 or 12 repeated assessments. Phase B will comprise 20, 17 or 14 assessments, respectively, so that each participant completes a total of 26 assessments.
During Phase A, participants in the oxazepam SCED may receive appropriate non-pharmacological usual-care interventions, such as psychological support, relaxation techniques, sophrology or psychotherapy, according to their clinical needs. If immediate pharmacological treatment becomes necessary, the participant will discontinue the study and receive the appropriate treatment without delay.
Medication doses will be adjusted by the investigator according to usual clinical practice, treatment efficacy and tolerability, within the limits defined in the relevant Summary of Product Characteristics and the dose-titration schedules specified in the protocol. Dose changes, dates and reasons for adjustment will be documented in the electronic case report form.
Each assessment session will include: tablet-based motor learning tasks: the Serial Reaction Time Task and Target Jump Task; TMS/PAS assessment of cortical excitability and plasticity; standardized collection of adverse events.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Emmeline Montané, MD
- Telefonnummer: +33 05 61 77 90 02
- E-mail: montane.e@chu-toulouse.fr
Studiesteder
-
-
-
Toulouse, Frankrig, 31 059
- Raymonde Fournet Purpan Hospital - Toulouse University Hospital
-
Kontakt:
- Emmeline Montané, MD
- Telefonnummer: +33 05 61 77 90 02
- E-mail: montane.e@chu-toulouse.fr
-
Ledende efterforsker:
- Emmeline Montané, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Adults (≥18 years) with ischemic or hemorrhagic stroke in the subacute phase (2 weeks-6 months)
- Non-urgent clinical indication for oxazepam, baclofen or gabapentin, with the protocol-defined treatment initiation interval considered medically acceptable by the investigator
- PGI-S score of at least 2 for the symptom leading to treatment prescription
- Ability to understand and consent (BDAE score >3)
- Brain MRI available for neuronavigation
- No motor impairment in the non-paretic hand
- Affiliation with a national health insurance system
- Free, informed and written informed consent signed by the participant and the investigator (at the latest on the day of inclusion and before any review required by the research).
Exclusion Criteria:
-
Current or recent treatment, within the previous 7 days, with a gabaergic drug of interest (oxazepam, gabapentin, baclofen)
-
Current or recent treatment, within the previous 7 days, with any prohibited treatment (benzodiazepine, Z-drug, morphine, pregabalin, sedative antipsychotic or barbiturate).
-
History of neurological disorders other than stroke, for example: neurodegenerative disease, multiple sclerosis, epilepsy, brain tumour, hydrocephalus.
-
History of severe psychiatric conditions, such as schizophrenia or bipolar disorder
-
Need for immediate initiation of the planned medication
- Oxazepam: severe respiratory failure, untreated sleep apnoea syndrome, severe acute or chronic hepatic impairment, myasthenia gravis, hypersensitivity to oxazepam or any excipient, galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption
- Baclofen: hypersensitivity to baclofen or any excipient, wheat allergy, or coeliac disease
- Gabapentin: hypersensitivity to gabapentin or any excipient, galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption
-
Presence of a psychoactive substance dependence
-
Pregnancy or breast-feeding
-
Skin disorder in the stimulated hand indicating the placement of electromyographic collection or stimulation electrodes
-
Medical contraindications for the performance of MSDs according to the TMS safety questionnaire
-
Presence of a major peripheral neuromuscular disorder (e.g. severe motor neuropathy) making the interpretation of PEM unreliable.
-
Guardianship, curatorship, safeguarding of justice
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Baclofen SCED
The patient will undergo two phases. The duration of phase A, baseline without treatment, will be randomized to 6, 9 or 12 repeated measures. The duration of phase B, baclofen intake, will be randomized to 20, 17 or 14 repeated measures. Each participant will serve as their own control, allowing within-subject comparison of outcomes before and after treatment introduction. |
Each participant undergoes repeated assessments of cortical plasticity (TMS/PAS) and motor learning (SRTT and Target Jump Task) across two consecutive phases:
|
|
Eksperimentel: Oxazepam SCED
The patient will undergo two phases. The duration of phase A, baseline without treatment, will be randomized to 6, 9 or 12 repeated measures. The duration of phase B, oxazepam intake, will be randomized to 20, 17 or 14 repeated measures. Each participant will serve as their own control, allowing within-subject comparison of outcomes before and after treatment introduction. |
Each participant undergoes repeated assessments of cortical plasticity (TMS/PAS) and motor learning (SRTT and Target Jump Task) across two consecutive phases:
|
|
Eksperimentel: Gabapentin SCED
The patient will undergo two phases. The duration of phase A, baseline without treatment, will be randomized to 6, 9 or 12 repeated measures. The duration of phase B, gabapentin intake, will be randomized to 20, 17 or 14 repeated measures. Each participant will serve as their own control, allowing within-subject comparison of outcomes before and after treatment introduction. |
Each participant undergoes repeated assessments of cortical plasticity (TMS/PAS) and motor learning (SRTT and Target Jump Task) across two consecutive phases:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Brain plasticity
Tidsramme: 6 weeks
|
It will be assessed by the change in the amplitude of the motor evoked potential (MEP) induced by a Paired Associative Stimulation (PAS) protocol, expressed as the percentage change between the pre-PAS and post-PAS measurements. The variation represents the degree of brain plasticity induced by the PAS protocol during a session. It will be done during all the assessments of phase A and phase B. |
6 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Cortical excitability: Membrane excitability of neurons in the motor cortex
Tidsramme: 6 weeks
|
It will be assessed by the Resting Motor Threshold (RMT), defined as the minimum stimulation intensity, expressed as a percentage of the Maximum Stimulator Output (MSO), that elicits at least 5 motor evoked potentials (PEM) ≥ 50 µV in 10 trials. It will be done during each session of phase A and phase B (except on the last day of each phase). |
6 weeks
|
|
Cortical excitability: Changes in cortical membrane excitability induced by the PAS protocol
Tidsramme: 6 weeks
|
It will be assessed by the change (Δ) in RMT induced by the PAS protocol, expressed as the percentage change between the RMT measured immediately after PAS and the RMT measured before PAS. It will be done during each session of phase A and phase B (except on the last day of each phase). |
6 weeks
|
|
Cortical excitability: Overall response of the corticospinal tract
Tidsramme: 6 weeks
|
It will be assessed by the PEM amplitude at the RMT, defined as the "peak-to-peak" average (µV) calculated from a series of 20 PEMs recorded at the RMT. It will be done during each session of phase A and phase B (except on the last day of each phase). |
6 weeks
|
|
Cortical excitability: Conduction and functional integrity of corticospinal tracts
Tidsramme: 6 weeks
|
It will be assessed by the PEM latency at the RMT, defined as the time (ms) between the magnetic pulse and the onset of the muscle response, averaged over 20 trials. It will be done during each session of phase A and phase B (except on the last day of each phase). |
6 weeks
|
|
Motor learning performance: general learning effect assessed by SRTT
Tidsramme: 6 weeks
|
The general learning effect will be assessed by Serial Reaction Time Task SRTT. It will be evaluated during each session of phase A and phase B (except on the last day of each phase). Specifically, this criterion will be evaluated by the decrease in normalized reaction time (%mRT) between block 2 and block 4 (sequence). During the SRTT, the participant must slide their finger from one position to another as quickly as possible, in response to a visual stimulus appearing at one of the four locations on the screen. In the sequenced condition, a sequence of 8 movements is repeated six times per block, while in the random condition, the 48 positions appear in a random order. The blocks follow the same alternation (R-S-S-S-R-S), allowing for the isolation of effects related to the learning of motor sequences. |
6 weeks
|
|
Motor learning performance: specific learning effect assessed by SRTT
Tidsramme: 6 weeks
|
The specific learning effect will be assessed by Serial Reaction Time Task SRTT. It will be evaluated during each session of phase A and phase B (except on the last day of each phase). Specifically, this criterion will be evaluated by the increase in %mRT in block 5 (random) compared to block 4 (sequence). |
6 weeks
|
|
Motor learning performance: retention assessed by SRTT
Tidsramme: 6 weeks
|
The retention will be assessed by Serial Reaction Time Task SRTT. It will be evaluated during each session of phase A and phase B (except on the last day of each phase). Specifically, this criterion will be evaluated by the change in %mRT between block 6 (sequence) and block 5 (random). |
6 weeks
|
|
Motor learning performance: general learning effect assessed by Target Jump tasks
Tidsramme: 6 weeks
|
The general learning effect will be assessed by Target Jump tasks. It will be evaluated during each session of phase A and phase B (except on the last day of each phase). Specifically, this criterion will be evaluated by the decrease in normalized reaction time (%mRT) between block 2 and block 4 (sequence). During the Target Jumps tasks, the participant must return their finger to the lower center of the screen before each trial, then slide it toward the target that appears. The target shifts a few centimeters as the participant begins the movement. The blocks alternate according to the pattern R-S-S-S-R-S, with random or systematic shifts, allowing for the exploration of visuomotor adaptation abilities. |
6 weeks
|
|
Motor learning performance: specific learning effect assessed by Target Jump tasks
Tidsramme: 6 weeks
|
The specific learning effect will be assessed by Target Jump tasks. It will be evaluated during each session of phase A and phase B (except on the last day of each phase). Specifically, this criterion will be evaluated by the increase in %mRT in block 5 (random) compared to block 4 (sequence). |
6 weeks
|
|
Motor learning performance: retention assessed by Target Jump tasks
Tidsramme: 6 weeks
|
The retention will be assessed by Target Jump tasks. It will be evaluated during each session of phase A and phase B (except on the last day of each phase). Specifically, this criterion will be evaluated by the change in %mRT between block 6 (sequence) and block 5 (random). |
6 weeks
|
|
Severity of the symptom that lead to initial treatment prescription
Tidsramme: 6 weeks
|
It will be reported by the patient using the Patient Global Impression of Severity PGI-S completed at inclusion, on the last day of phase A and last day of phase B. This scale ranges from 1 ("no discomfort/pain/anxiety") to 4 ("severe"). Each patient will complete only one PGI-S form, corresponding to the symptom being treated by the study drug. |
6 weeks
|
|
Safety of participants
Tidsramme: 6 weeks
|
It will be assessed by the spontaneous report on adverse events, assessed at each session. |
6 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Emmeline Montané, MD, University Hospital, Toulouse
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Smerte
- Neurologiske manifestationer
- Muskuloskeletale sygdomme
- Cerebrovaskulære lidelser
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Karsygdomme
- Hjerte-kar-sygdomme
- Muskelsygdomme
- Muskelhypertoni
- Neuromuskulære manifestationer
- Psykiske lidelser
- Neuromuskulære sygdomme
- Sygdomme i det perifere nervesystem
- Patologiske tilstande, tegn og symptomer
- Tegn og symptomer
- Muskelspasticitet
- Slag
- Angstlidelser
- Neuralgi
- Aminosyrer, peptider og proteiner
- Organiske kemikalier
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Kulbrinter
- Cyclohexanes
- Cycloparaffiner
- Kulbrinter, alicyklisk
- Kulbrinter, cyklisk
- Syrer, acyklisk
- Carboxylsyrer
- Aminer
- Aminosyrer
- Benzazepiner
- Gamma-Aminobutyric Acid
- Aminobutyrater
- Butyrater
- Syrer, carbocykliske
- Benzodiazepiner
- Cyclohexanecarboxylsyrer
- Benzodiazepinoner
- Gabapentin
- Baclofen
- Oxazepam
Andre undersøgelses-id-numre
- RC31/25/0619
- 2026-526884-39-00 (Anden identifikator: EU-CT)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .